Jiali Hu

Jiali Hu

Auto-generated profile, based on publicly available information

Jiali Hu

Guangdong Provincial Key Laboratory of Tumour Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai, 519000, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
XDXiaobing Duan
Xiaobing Duan
JHJiali Hu
Jiali Hu
YZYuncong Zhang
Yuncong Zhang
XZXiaoguang Zhao
Xiaoguang Zhao
MYMingqi Yang
Mingqi Yang
LLLigong Lu
Ligong Lu
Retinoic acid-inducible gene I (RIG-I) is a pattern recognition receptor involved in innate immunity, but its role in adaptive immunity, specifically in the context of CD8 + T-cell antitumour immunity, remains unclear. Here, we demonstrate that RIG-I is upregulated in tumour-infiltrating CD8 + T cells, where it functions as an intracellular checkpoint to negatively regulate CD8 + T-cell function and limit antitumour immunity. Mechanistically, the upregulation of RIG-I in CD8 + T cells is induced by activated T cells, and directly inhibits the AKT/glycolysis signalling pathway. In addition, knocking out RIG-I enhances the efficacy of adoptively transferred T cells against solid tumours, and inhibiting RIG-I enhances the response to PD-1 blockade. Overall, our study identifies RIG-I as an intracellular checkpoint and a potential target for alleviating inhibitory constraints on T cells in cancer immunotherapy, either alone or in combination with an immune checkpoint inhibitor.